BFRI vs. NCNA, TRVN, CVKD, VIRI, BNOX, CYCN, GRAY, VCNX, EFTR, and HEPA
Should you be buying Biofrontera stock or one of its competitors? The main competitors of Biofrontera include NuCana (NCNA), Trevena (TRVN), Cadrenal Therapeutics (CVKD), Virios Therapeutics (VIRI), Bionomics (BNOX), Cyclerion Therapeutics (CYCN), Graybug Vision (GRAY), Vaccinex (VCNX), eFFECTOR Therapeutics (EFTR), and Hepion Pharmaceuticals (HEPA). These companies are all part of the "medical" sector.
NuCana (NASDAQ:NCNA) and Biofrontera (NASDAQ:BFRI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, community ranking, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.
NuCana has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500. Comparatively, Biofrontera has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500.
44.0% of NuCana shares are owned by institutional investors. Comparatively, 10.1% of Biofrontera shares are owned by institutional investors. 31.2% of NuCana shares are owned by company insiders. Comparatively, 0.2% of Biofrontera shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, NuCana and NuCana both had 4 articles in the media. Biofrontera's average media sentiment score of 0.75 beat NuCana's score of -0.75 indicating that NuCana is being referred to more favorably in the media.
NuCana currently has a consensus target price of $125.00, indicating a potential upside of 3,471.43%. Biofrontera has a consensus target price of $18.00, indicating a potential upside of 1,566.67%. Given Biofrontera's higher probable upside, analysts plainly believe NuCana is more favorable than Biofrontera.
NuCana has a net margin of 0.00% compared to NuCana's net margin of -69.44%. Biofrontera's return on equity of -124.81% beat NuCana's return on equity.
Biofrontera has higher revenue and earnings than NuCana. NuCana is trading at a lower price-to-earnings ratio than Biofrontera, indicating that it is currently the more affordable of the two stocks.
NuCana received 242 more outperform votes than Biofrontera when rated by MarketBeat users. Likewise, 67.57% of users gave NuCana an outperform vote while only 60.00% of users gave Biofrontera an outperform vote.
Summary
NuCana beats Biofrontera on 12 of the 15 factors compared between the two stocks.
Get Biofrontera News Delivered to You Automatically
Sign up to receive the latest news and ratings for BFRI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BFRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biofrontera Competitors List
Related Companies and Tools
